QTTB: Bempikibart demonstrates strong efficacy and safety in alopecia areata, with phase III set for next year
Recent 36-week data in alopecia areata show bempikibart matches JAK efficacy with a better safety profile, targeting a growing multibillion-dollar US market. Phase III is planned for next year, with additional indications and 52-week durability data upcoming.Based on Q32 Bio Inc. [QTTB] 12th Annual…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.